Rituximab for the treatment of patients with chronic lymphocytic leukemia

References

• RedaelliALaskinBLStephensJMThe clinical and epidemiological burden of chronic lymphocytic leukaemiaEur J Cancer Care200413279287
   PubMed Web of Science ®Google Scholar
• CatovskyDFoaRThe Lymphoid LeukaemiasLondonButterworths1990
   Google Scholar
• MauroFRFoaRGiannarelliDClinical characteristics and outcome of young chronic lymphocytic leukemia patients: a single institution study of 204 casesBlood19999444845410397712
   PubMed Web of Science ®Google Scholar
• GreverMRKopeckyKJColtmanCAFludarabine monophosphate: a potentially useful agent in chronic lymphocytic leukemiaNouv Rev Fr Hematol1988304574592464793
   PubMedGoogle Scholar
• KeatingMJO’BrienSLernerSLong-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapyBlood199892116511719694704
   PubMed Web of Science ®Google Scholar
• JohnsonSSmithAGLofflerHMulticentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLLLancet1996347143214388676625
   PubMed Web of Science ®Google Scholar
• RaiKRPetersonBLAppelbaumFRFludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemiaN Engl J Med20003431750175711114313
   PubMed Web of Science ®Google Scholar
• LeporrierMChevretSCazinBRandomized comparison of fludarabine, CAP, and CHOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patientsBlood2001982319232511588025
   PubMed Web of Science ®Google Scholar
• HuhnDVon SchillingCWilhelmMRituximab therapy of patients with B-cell chronic lymphocytic leukemiaBlood2001981326133111520778
   PubMed Web of Science ®Google Scholar
• HainsworthJDLitchySBartonJHSingle-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research NetworkJ Clin Oncol2003211746175112721250
   PubMed Web of Science ®Google Scholar
• O’BrienSMKantarjianHThomasDARituximab dose-escalation trial in chronic lymphocytic leukemiaJ Clin Oncol2001192165217011304768
   PubMed Web of Science ®Google Scholar
• ByrdJCMurphyTHowardRSRituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicityJ Clin Oncol2001192153216411304767
   PubMed Web of Science ®Google Scholar
• ByrdJCPetersonBLMorrisonVLRandomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712)Blood2003119976984
   Google Scholar
• ByrdJCRaiKPetersonBLThe addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011Blood2005105495315138165
   PubMed Web of Science ®Google Scholar
• KeatingMJO’BrienSAlbitarMEarly results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemiaJ Clin Oncol2005234079408815767648
   PubMed Web of Science ®Google Scholar
• WierdaWO’BrienSWenSChemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocyticleukemiaJ Clin Oncol2005234070407815767647
   PubMed Web of Science ®Google Scholar
• ByrdJCGribbenJGPetersonBLGreverMRLozanskiGLucasDMSelect high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapyJ Clin Oncol20062443744316344317
   PubMed Web of Science ®Google Scholar
• SchulzHKleinSKRehwaldUReiserMHinkeAKnaufWUPhase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemiaBlood20021003115312012384407
   PubMed Web of Science ®Google Scholar
• TamCSO’BrienSWierdaWLong-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemiaBlood200811297598018411418
   PubMed Web of Science ®Google Scholar
• HallekMFingerle-RowsonGFinkAMFirst-line treatment with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) improves overall survival (OS) in previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL): results of a randomized phase III trial on behalf of an international group of investigators and the German CLL Study Group. [abstract]Blood2009535a
   Web of Science ®Google Scholar
• FoonKABoyiadzisMLandSRChemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemiaJ Clin Oncol20092749850319075274
   PubMed Web of Science ®Google Scholar
• LamannaNJurcicJGNoyASequential therapy with fludarabine, high-dose cyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemia produces high-quality responses: molecular remissions predict for durable complete responsesJ Clin Oncol20092749149719075280
   PubMed Web of Science ®Google Scholar
• BoschFAbrisquetaPVillamorNRituximab, fludarabine, cyclophosphamide, and mitoxantrone: a new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemiaJ Clin Oncol2009274578458419704063
   PubMed Web of Science ®Google Scholar
• FaderlSWierdaWO’BrienSFerrajoliALernerSKeatingMJFludarabine, cyclophosphamide, mitoxantrone plus rituximab (FCM-R) in frontline CLL <70 yearsLeuk Res20103428428819646755
   PubMed Web of Science ®Google Scholar
• LamannaNKalaycioMMaslakPPentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemiaJ Clin Oncol2006241575178116520464
   PubMed Web of Science ®Google Scholar
• KayNEGeyerSMCallTGCombination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemiaBlood200710940541117008537
   PubMed Web of Science ®Google Scholar
• ShanafeltTDLinTGeyerSMPentostatin, cyclophosphamide, and rituximab regimen in older patients with chronic lymphocytic leukemiaCancer20071092291229817514743
   PubMed Web of Science ®Google Scholar
• ReffMECarnerKChambersKSDepletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20Blood1994834354457506951
   PubMed Web of Science ®Google Scholar
• AndersonKCBatesMPSlaughenhouptBLExpression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiationBlood198463142414336609729
   PubMed Web of Science ®Google Scholar
• NadlerLMRitzJHardyRA unique cell surface antigen identifying lymphoid malignancies of B cell originJ Clin Invest1981671341406969730
   PubMed Web of Science ®Google Scholar
• PetrykMGrossbardMLRituximab therapy of B-cell neoplasmsClin Lymphoma2000118619411707828
   PubMedGoogle Scholar
• AlmasriNMDuqueREIturraspeJReduced expression of CD20 antigen as a characteristic marker for chronic lymphocytic leukemiaAm J Hematol1992402592631380203
   PubMed Web of Science ®Google Scholar
• BeumPVLindorferMABeurskensFComplement activation on B lymphocytes opsonized with rituximab or ofatumumab produces substantial changes in membrane structure preceding cell lysisJ Immunol200818182283218566448
   PubMed Web of Science ®Google Scholar
• PloskerGLFiggittDPRituximab: a review of its use in non-Hodgkin’s lymphoma and chronic lymphocytic leukaemiaDrugs20036380384312662126
   PubMed Web of Science ®Google Scholar
• MaloneyDGSmithBRoseARituximab: mechanism of action and resistanceSemin Oncol2002291 Suppl 22911842383
   PubMed Web of Science ®Google Scholar
• CartronGDacheuxLSallesGTherapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa geneBlood200299754811806974
   PubMed Web of Science ®Google Scholar
• CarlottiEPalumboGAOldaniEFcgammaRIIIA and FcgammaRIIA polymorphisms do not predict clinical outcome of follicular non-Hodgkin’s lymphoma patients treated with sequential CHOP and rituximabHaematologica2007921127113017650444
   PubMed Web of Science ®Google Scholar
• AlasSEmmanouilidesCBonavidaBInhibition of interleukin 10 by rituximab results indown-regulation of bcl-2 and sensitization of B-cell non-Hodgkin’s lymphoma to apoptosisClin Cancer Res2001770972311297268
   PubMed Web of Science ®Google Scholar
• McLaughlinPGrillo-LopezAJLinkBKRituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment programJ Clin Oncol199816282528339704735
   PubMed Web of Science ®Google Scholar
• DaydéDTernantDOhresserMTumor burden influences exposure and response to rituximab: pharmacokinetic-pharmacodynamic modeling using a syngeneic bioluminescent murine model expressing human CD20Blood20091133765377219029438
   PubMed Web of Science ®Google Scholar
• FustGCzinkEMinhDDepressed classical complement pathway activities in chronic lymphocytic leukemiaClin Exp Immunol1985604894954017286
   PubMed Web of Science ®Google Scholar
• KlepfishAGillesLIoannisKEliezerRAmiSEnhancing the action of rituximab in chronic lymphocytic leukemia by adding fresh frozen plasma: complement/rituximab interactions and clinical results in refractory CLLAnn N Y Acad Sci2009117386587319758239
   PubMed Web of Science ®Google Scholar
• MaloneyDGLilesTMCzerwinskiDKPhase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphomaBlood199484245724667522629
   PubMed Web of Science ®Google Scholar
• MaloneyDGGrillo-LopezAJBodkinDJIDECC2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin’s lymphomaJ Clin Oncol199715326632749336364
   PubMed Web of Science ®Google Scholar
• MaloneyDGGrillo-LopezAJWhiteCAIDECC2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin’s lymphomaBlood199790218821959310469
   PubMed Web of Science ®Google Scholar
• Grillo-LopezAJRituximab: an insider’s historical perspectiveSemin Oncol20002791611226006
   PubMed Web of Science ®Google Scholar
• McLaughlinPWhiteCAGrillo-LopezAJMaloneyDGClinical status and optimal use of rituximab for B-cell lymphomasOncology (Williston Park)199812176317699874849
   PubMed Web of Science ®Google Scholar
• NguyenDTAmessJADoughtyHHendryLDiamondLWIDEC-C2B8 anti-CD20 (rituximab) immunotherapy in patients with low-grade non-Hodgkin’s lymphoma and lymphoproliferative disorders: evaluation of response on 48 patientsEur J Haematol199962768210052709
   PubMed Web of Science ®Google Scholar
• WinklerUJensenMManzkeOSchulzHDiehlVEngertACytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8)Blood1999942217222410498591
   PubMed Web of Science ®Google Scholar
• LadettoMBerguiLRiccaICampanaSPileriATarellaCRituximab anti-CD20 monoclonal antibody induces marked but transient reductions of peripheral blood lymphocytes in chronic lymphocytic leukaemia patientsMed Oncol20001720321010962531
   PubMed Web of Science ®Google Scholar
• ItalaMGeislerCHKimbyEStandard-dose anti-CD20 antibody rituximab has efficacy in chronic lymphocytic leukaemia: results from a Nordic multicentre studyEur J Haematol20026912913412406005
   PubMed Web of Science ®Google Scholar
• ThomasDO’BrienSGilesFJSingle agent rituxan in early stage chronic lymphocytic leukemia (CLL). [abstract]Blood200198364a
   Google Scholar
• ByrdJCSmithLHackbarthMLFlinnIWYoungDProffittJHInterphase cytogenetic abnormalities in chronic lymphocytic leukemia may predict response to rituximabCancer Res200363363812517774
   PubMed Web of Science ®Google Scholar
• O’BrienSMKantarjianHMCortesJResults of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemiaJ Clin Oncol2001191414142011230486
   PubMed Web of Science ®Google Scholar
• TsimberidouAMTamCAbruzzoLVChemoimmunotherapy may overcome the adverse prognostic significance of 11q deletion in previously untreated patients with chronic lymphocytic leukemiaCancer20091153738019117034
   PubMed Web of Science ®Google Scholar
• LinKITamCSKeatingMJRelevance of the immunoglobulin VH somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimensBlood200911331687119050308
   PubMed Web of Science ®Google Scholar
• KnaufWULissichkovTAldaoudAPhase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemiaJ Clin Oncol2009 102743788419652068
   PubMed Web of Science ®Google Scholar
• FischerKCramerPStilgenbauerSBendamustine combined with rituximab (BR) in first-line therapy of advanced CLL: a multicenter phase II trial of the German CLL Study Group (GCLLSG). [abstract]Blood2009114205a
   Web of Science ®Google Scholar
• CastroJEJamesDFSandoval-SusJDJainSBoleJRassentiLKippsTJRituximab in combination with high-dose methylpredniso-lone for the treatment of chronic lymphocytic leukemiaLeukemia2009231779178919693094
   PubMed Web of Science ®Google Scholar
• ShanDLedbetterJAPressOWSignaling events involved in anti-20-induced apoptosis of malignant human B cellsCancer Immunol Immunother20004867368310752475
   PubMed Web of Science ®Google Scholar
• HofmeisterJKCooneyDCoggeshallKMClustered CD20 induced apoptosis: src-family kinase, the proximal regulator of tyrosine phosphorylation, calcium influx, and caspase 3-dependent apoptosisBlood Cells Mol Dis20002613314310753604
   PubMed Web of Science ®Google Scholar
• GolayJZaffaroniLVaccariTLazzariMBorleriGMBernasconiSBiologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysisBlood2000953900390810845926
   PubMed Web of Science ®Google Scholar
• TangyeSGRaisonRLHuman cytokines suppress apoptosis of leukaemic CD5+ B cells and preserve expression of bcl-2Immunol Cell Biol1997751271359107564
   PubMed Web of Science ®Google Scholar
• AdamiFGuariniAPiniMSivieroFSancettaRMassaiaMSerum levels of tumour necrosis factor-alpha in patients with B-cell chronic lymphocytic leukaemiaEur J Cancer199430A125912637999409
   PubMed Web of Science ®Google Scholar
• WoyachJALinTSLucasMSA phase I/II study of rituximab and etanercept in patients with chronic lymphocytic leukemia and small lymphocytic lymphomaLeukemia20092391291819225537
   PubMed Web of Science ®Google Scholar
• LundinJOsterborgABrittingerGCAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin’s lymphomas: a phase II multicenter studyJ Clin Oncol199816325732639779699
   PubMed Web of Science ®Google Scholar
• FaderlSThomasDAO’BrienSExperience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignanciesBlood20031013413341512522009
   PubMed Web of Science ®Google Scholar
• ZentCSCallTGShanafeltTDEarly treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximabCancer20081132110211818759253
   PubMed Web of Science ®Google Scholar
• WierdaWGO’BrienSFaderlSFerrajoliARavandi-KashaniFCortesJCombined cyclophosphamide, fludarabine, alemtuzumab, and rituximab (CFAR), an active regimen for heavily treated patients with CLL. [abstract]Blood200610814a
   Web of Science ®Google Scholar
• WierdaWGO’BrienSFerrajoliACombined Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR), an Active Frontline Regimen for High-Risk Patients with CLL. [abstract]Blood2007110628a
   Web of Science ®Google Scholar
• ByrdJCKippsTJFlinnIWPhase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemiaBlood201011548949519843887
   PubMed Web of Science ®Google Scholar
• CatovskyDRichardsSMatutesEAssessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trialLancet200737023023917658394
   PubMed Web of Science ®Google Scholar
• EichhorstBFBuschRStilgenbauerSFirst-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemiaBlood20091143382339119605849
   PubMed Web of Science ®Google Scholar
• GhielminiMSchmitzSFCogliattiSBProlonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 scheduleBlood20041034416442314976046
   PubMed Web of Science ®Google Scholar
• HainsworthJDLichtySShafferDWMaximizing therapeutic benefit of rituximab maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin’s lymphoma – a randomized phase II trial of the Minnie Pearl Cancer Research NetworkJ Clin Oncol2005231088109515657401
   PubMed Web of Science ®Google Scholar
• Del PoetaGDel PrincipeMIRagusaDRituximab maintenance following chemoimmunotherapy improves outcome in B-cell chronic lymphocytic leukemia. [abstract]Blood20091142364a19762499
   PubMed Web of Science ®Google Scholar
• MauroFRDel GiudiceIGentileMPost-remissional rituximab administration for the treatment of older chronic lymphocytic leucemia (CLL) patients responsive to first-line therapy with chlorambucil and prednisone. [abstract]Haematologica200744124a
   Google Scholar
• KhouriIFSalibaRMAdmirandJGraft-versus leukaemia effect after non-myeloablative haematopoietic transplantation can overcome the unfavourable expression of ZAP-70 in refractory chronic lymphocytic leukaemiaBr J Haematol200713735536317456058
   PubMed Web of Science ®Google Scholar
• ClynesRATowersTLPrestaLGRavetchJVInhibitory Fc receptors modulate in vivo toxicity against tumor targetsNat Med2000644344610742152
   PubMed Web of Science ®Google Scholar
• PfeifferMStanojevicSFeuchtingerTGreilJRituximab mediates in vitro antileukemic activity in pediatric patients after allogeneic transplantationBone Marrow Transplant200536919715908973
   PubMed Web of Science ®Google Scholar
• HsuFJKomarovskayaMCTLA4 blockade maximizes antitumor T-cell activation by dendritic cells presenting idiotype protein or opsonized anti-CD20 antibody-coated lymphoma cellsJ Immunother20022545546812439343
   PubMed Web of Science ®Google Scholar
• TeelingJLMackusWJWiegmanLJThe biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20J Immunol200617736237116785532
   PubMed Web of Science ®Google Scholar
• TeelingJLFrenchRRCraggMSCharacterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomasBlood20041041793180015172969
   PubMed Web of Science ®Google Scholar